Medication adherence in gout: A systematic review

Arthritis Care and Research

Volumn 66, Issue 10, 2014, Pages 1551-1559

  De Vera, Mary A ^a,b   Marcotte, Greg ^a   Rai, Sharan ^b   Galo, Jessica S ^a   Bhole, Vidula ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; COLCHICINE; URIC ACID; BIOLOGICAL MARKER;

AGE DISTRIBUTION; COMORBIDITY; DRUG WITHDRAWAL; ELECTRONIC PRESCRIBING; FOLLOW UP; GOUT; HUMAN; HYPERTENSION; MEDICATION COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE DATABASE; REVIEW; SAMPLE SIZE; SELF REPORT; STUDY DESIGN; SYSTEMATIC REVIEW; TREATMENT REFUSAL; URIC ACID BLOOD LEVEL; BLOOD; MULTIVARIATE ANALYSIS; RISK FACTOR; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; GOUT; GOUT SUPPRESSANTS; HUMANS; MEDICATION ADHERENCE; MULTIVARIATE ANALYSIS; RISK FACTORS; TREATMENT OUTCOME; URIC ACID;

EID: 84908546441     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22336     Document Type: Review

References (40)

1. Choi H, Curhan G. Gout: epidemiology and lifestyle choices. Curr Opin Rheumatol 2005;17:341-5.
2. Choi H, Mount D, Reginato A. Pathogenesis of gout. Ann Intern Med 2005;143:499-516.
3. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011;63:3136-41.
4. Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology (Oxford) 2009;48 Suppl 2:ii9-14.
5. Khanna D, Khanna PP, FitzGerald JD, Singh MK, Bae S, Neogi T. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012;64:1447-61.
6. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
7. Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, et al. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol 2009; 36:1032-40.
8. Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, et al. Treatment of chronic gout: can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001;28:577-80.
9. Doherty M, Jansen T, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis 2012;71:1765-70.
10. Neogi T, Hunter D, Chaisson C, Allensworth-Davies D, Zhang Y. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006;33:104-9.
11. Osterberg L, Blaschke T. Adherence to medication. New Engl J Med 2005;353:487-97.
12. Urquhart J, Vrijens B. New findings about patient adherence to prescribed drug dosing regimens: an introduction to pharmionics. Eur J Hosp Pharm Sci 2005;11:103-6.
13. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7.
14. Briesacher B, Andrade S, Fouayzi H, Chan K. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008;28:437-43.
15. Harrold L, Andrade S. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum 2009;38:396-402.
16. Ho P, Bryson C, Rumsfeld J. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119: 3028-35.
17. Sabate E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.
18. Hess L, Raebel M, Conner D, Malone D. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40:1280-8.
19. Peterson A, Nau D, Cramer J, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12.
20. Riedel A, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004;31:1575-81.
21. Sarawate C, Brewer K, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-34.
22. Solomon D, Avorn J, Levin R, Brookhart M. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis 2008;67:609-13.
23. Park H, Rascati KL, Prasla K, McBayne T. Evaluation of health care costs and utilization patterns for patients with gout. Clin Ther 2012;34:640-52.
24. Zandman-Goddard G, Amital H, Shamrayevsky N, Raz R, Shalev V, Chodick G. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel. Rheumatology (Oxford) 2013;52:1126-31.
25. Halpern R, Mody R, Fuldeore M, Patel P, Mikuls T. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin 2009;25:1711-9.
26. Singh J, Hodges J, Asch S. Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis 2009;68: 1265-70.
27. Harrold L, Andrade S, Briesacher B, Raebel MA, Fouayzi H, Yood RA, et al. The dynamics of chronic gout treatment: medication gaps and return to therapy. Am J Med 2010;123: 54-9.
28. Karve S, Cleves M, Helm M, Hudson T, West D, Martin B. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009;25:2303-10.
29. Deyo R, Inui T, Sullivan B. Noncompliance with arthritis drugs: magnitude, correlates, and clinical implications. J Rheumatol 1981;8:931-6.
30. De Klerk E, van der Heijde D, Landewe R, van der Tempel H, Urquhart J, van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003;30:44-54.
31. Silva L, Miguel E, Peiteado D, Villalba A, Mola M, Pinto J, et al. Compliance in gout patients. Acta Reumatol Port 2010;35: 466-74.
32. Dalbeth N, Petrie KJ, House M, Chong J, Leung W, Chegudi R, et al. Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Arthritis Care Res (Hoboken) 2011;63:1605-12.
33. Thompson K, Kulkarni J, Sergejew A. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 2000;42:241-7.
34. Dalbeth N, House M, Horne A, Petrie K, McQueen F, Taylor W. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout. BMC Musculoskelet Disord 2012;13:174-7.
35. Martini N, Bryant L, Te Karu L, Aho L, Chan R, Miao J, et al. Living with gout in New Zealand: an exploratory study into people's knowledge about the disease and its treatment. J Clin Rheumatol 2012;18:125-9.
36. Harrold L, Andrade S, Briesacher B, Raebel MA, Fouayzi H, Yood RA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009;11:R46-52.
37. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-24.
38. Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a metaanalysis of prevalence and clinical consequences. Eur Heart J 2013;34:2940-8.
39. Kauric-Klein Z. Predictors of nonadherence with blood pressure regimens in hemodialysis. Patient Prefer Adherence 2013;7:973-80.
40. Reach G. Treatment adherence in patients with gout. Joint Bone Spine 2011;78:456-9.